Keywords: benefit, study, add, value, tracleer, actelion, cteph
BENEFiT study could add value to Tracleer for Actelion with CTEPH indication
Article | 04 June 2007
Results of the Phase III BENEFiT study exploring Swiss company Actelion's dual endothelin receptor antagonist Tracleer (bosentan) as a treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
